Thermo Fisher Scientific Inc., commonly known as TMO, is a premier American provisioner of scientific research services. Incorporated in 1956 and headquartered in Waltham, Massachusetts, TMO has established itself as a prominent figure in the sphere of scientific research, specifically in the areas of genetic testing and precision laboratory equipment.
The financial robustness of TMO reflects its innovative endeavor in the scientific field. As of December 2020, the company boasted a revenue of 29.23 billion dollars, marking its considerable growth over the years. TMO's comprehensive array of products and services cater to a broad clientele that includes research and analytical laboratories, pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies, both domestically and internationally.
TMO's reputation as a global leader in science stems from its strong portfolio of premier brands such as Fisher Scientific, Applied Biosystems, Invitrogen, Thermo Scientific, and Unity Lab Services. These brands exemplify Thermo Fisher's commitment to capitalizing on scientific advancements for societal betterment. It is evident in the significant contributions they've made in various fields, ranging from complex disease research and drug discovery to food safety and environmental monitoring.
The extensive capabilities of TMO span across analytical instruments; reagents; consumables; software and services that are used in research, manufacturing, analysis, discovery, and diagnostics. Operative in over 50 countries with more than 75,000 employees worldwide, the company not only enjoys unmatched modulation but also possesses an inclusive global impact.
Boasting a strong presence in healthcare technology, TMO has been instrumental in providing critical services amidst global crises like the COVID-19 pandemic. By producing testing kits and developing treatments, Thermo Fisher has substantiated its mission of enabling customers to make the world healthier, cleaner, and safer.
A key to TMO's success is its investment in research and development, leading to the production of an assortment of innovative products. This is facilitated through strategic partnerships, acquisitions of complementary businesses, and deployment of respected brands to bolster its portfolio.
Thermo Fisher Scientific Inc. has proven time and again its capability to adapt and grow, exploiting opportunities to catalyze scientific discovery and improvement in the quality of life. This corporate juggernaut successfully marries its entrepreneurial mindset with its expanse of expertise, thereby cementing its status as a pioneering force in the global scientific community.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article compares Illumina (ILMN) and Thermo Fisher Scientific (TMO), two companies selling to drug developers and labs. While Illumina focuses on genetic sequencing machines and supplies, Thermo Fisher offers a broader range of lab instruments and drug development services. The analysis delves into their sales forecasts, financial health (margins and debt), and growth metrics to help investors decide which stock presents a better opportunity.
This article details Wall Street's top analyst upgrades, downgrades, and initiations for Friday, October 23, 2026, following a volatile week in financial markets. Key market movements included a plunge in Treasury yields, a surge in oil prices, significant crypto liquidations, and Meta's negative free cash flow impacting tech stocks. Noteworthy calls include SpaceX's upgrade to Buy with a significantly increased target price, alongside changes for companies like Deckers Outdoor, Globe Life, Guardant Health, and Thermo Fisher Scientific.
Life sciences firm Qiagen N.V. (NYSE: QGEN) has agreed to a 10.8 billion euros all-cash buyout from EQT AB (OTC: EQBBF) at 46.50 euros per share, representing a 40.3% premium. The Supervisory and Managing Boards unanimously endorsed the buyout, seeing it as a way to gain flexibility for long-term investment while providing attractive cash returns to shareholders. Analysts view the 15 times 2027 adjusted EBITDA valuation as reasonable, given Qiagen's lower relative growth profile compared to other life sciences deals.
BlossomHill Therapeutics has partnered with Foundation Medicine to develop a companion diagnostic (CDx) assay for the EGFR C797S resistance mutation. This assay will support the development of BlossomHill's investigational EGFR inhibitor, BH-30643, which has shown promising results in patients with EGFR C797S-positive NSCLC and has received US FDA Fast Track designation. BlossomHill plans to initiate a global Phase II study for BH-30643 in Q1 2027.
Thermo Fisher Scientific reported strong financial results for Q3 2026, with revenue growing 9% to $12.14 billion and adjusted EPS increasing by 15% to $6.68. The company's performance was driven by a proven growth strategy, including the launch of innovative products and strategic partnerships, such as the Precure initiative with Mayo Clinic. Thermo Fisher Scientific also advanced its global presence by opening an AI-Automation Innovation Center in South Korea and a highly automated distribution center in Kentucky.
Thermo Fisher Scientific Inc. reported strong Q3 2026 results, surpassing profit and revenue forecasts with an adjusted EPS of $6.68 and $12.14B in revenue. The company demonstrated solid operational execution, driven by 6.0% organic revenue growth and exceptional performance in its Laboratory Products and Biopharma Services segment. Despite the positive results, the stock saw a modest 1.2% increase, indicating investors may have already anticipated strong performance.